Shingles
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Dynavax TechnologiesCA - Emeryville
2 programs1
1
Z-1018Phase 1/21 trial
Z-1018Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.Zoster Vaccine Live
Dynavax TechnologiesZ-1018
Dynavax TechnologiesZ-1018
Clinical Trials (3)
Total enrollment: 924 patients across 3 trials
Immune Response to Shingles Vaccination
Start: Feb 2016Est. completion: Nov 201910 patients
Phase 4Completed
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
Start: Jun 2024Est. completion: Nov 2031764 patients
Phase 1/2Recruiting
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
Start: Jan 2022Est. completion: Oct 2022150 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 924 patients
2 companies competing in this space